Prospective Activity of PLG0206, an Engineered Antimicrobial Peptide, on Chronic Periprosthetic Joint Infection Total Knee Arthroplasty Components <i>Ex Vivo</i> : The Knee Explant Analysis (KnEA) Study
-
- David Huang
- Peptilogics, Pittsburgh, Pennsylvania, USA
-
- Dana M. Parker
- Arthritis and Arthroplasty Design Group, Department of Orthopedic Surgery, University of Pittsburgh, Pittsburgh, Pennsylvania, USA
-
- Jonathan B. Mandell
- Arthritis and Arthroplasty Design Group, Department of Orthopedic Surgery, University of Pittsburgh, Pittsburgh, Pennsylvania, USA
-
- Kimberly M. Brothers
- Arthritis and Arthroplasty Design Group, Department of Orthopedic Surgery, University of Pittsburgh, Pittsburgh, Pennsylvania, USA
-
- Charles G. Gish
- Arthritis and Arthroplasty Design Group, Department of Orthopedic Surgery, University of Pittsburgh, Pittsburgh, Pennsylvania, USA
-
- John A. Koch
- Arthritis and Arthroplasty Design Group, Department of Orthopedic Surgery, University of Pittsburgh, Pittsburgh, Pennsylvania, USA
-
- Nicholas Pachuda
- Peptilogics, Pittsburgh, Pennsylvania, USA
-
- Despina Dobbins
- Peptilogics, Pittsburgh, Pennsylvania, USA
-
- Jonathan Steckbeck
- Peptilogics, Pittsburgh, Pennsylvania, USA
-
- Kenneth L. Urish
- Arthritis and Arthroplasty Design Group, Department of Orthopedic Surgery, University of Pittsburgh, Pittsburgh, Pennsylvania, USA
-
- Jeanette W. P. Teo
- editor
抄録
<jats:p> Chronically infected prosthetics of the knee were exposed to PLG0206, an engineered antimicrobial peptide, at a concentration of 1 mg/mL for 15 min. Consequently, a mean 4-log <jats:sub>10</jats:sub> reduction (range, 1 to 7) in the number of bacteria occurred, which may translate to improved clinical outcomes for persons with prosthetic joint infection of the knee. </jats:p>
収録刊行物
-
- Microbiology Spectrum
-
Microbiology Spectrum 9 (3), e0187921-, 2021-12-22
American Society for Microbiology